Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01330966 · ClinicalTrials.gov registry record · Phase 2
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
A Phase 2 study, sponsored by Emerald Clinical.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01330966 is a Phase 2 study that has completed, run by Emerald Clinical. The registered enrollment target is 47 participants.
The verdict
NCT01330966, a Phase 2 study, has completed, sponsored by Emerald Clinical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
Interventions
- DRUG pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-04 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01330966
The ClinicalTrials.gov registry entry for NCT01330966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emerald Clinical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pazopanib is the first listed.
NCT01330966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01330966 about?
NCT01330966 is a clinical study titled "Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma". The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
What is the current status of trial NCT01330966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2011-04. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01330966?
The interventions under investigation include: pazopanib (DRUG).
Who is sponsoring clinical trial NCT01330966?
This trial is sponsored by Emerald Clinical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.